Research shows that racial disparities exist in the delivery of guideline-adherent cancer care, and that non-White patients are less likely to receive guideline-concordant care than White patients, leading to worse health outcomes. However, these disparities are not often addressed. The Elevating Cancer Equity initiative aims to address these disparities through policy-change recommendations developed by a working group and informed by data from patients/caregivers and oncologists. The hope is that the results of these surveys and the resultant recommendations will be a step toward cancer care equity in the United States.
Disclosures: Ms. Harrington has disclosed having an equity interest and stock options in Pfizer Inc. Dr. Winn has disclosed receiving honoraria from Genentech, Inc. The remaining presenters and moderator have disclosed that they have not received any financial consideration from any person or organization to support this presentation.
Funding: The Elevating Cancer Equity initiative is funded by grants from AbbVie, Bluebird bio, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Lilly, Merck, MorphoSys, Pfizer, Regeneron, Sanofi, and Taiho.